References
- 1. Provan D, Baglin T, Dokal I, et al. Oxford Handbook of Clinical Haematology, 4th ed. Oxford University Press, 2015; p. 336-361.
- 2. Palumbo A, Cerrato C. Diagnosis and therapy of multiple myeloma. Korean J Intern Med. 2013;28:263-273.
- 3. Bergsage D, Sprague C, Austin C, et al. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma: IV. L-Phenylalanine mustard (NC-8806). Cancer Chemotherapy Rep. 1962;21:87.
- 4. Rosignol L, Oriol A, Terulel A, et al. Superiority of bortezomib, thalidomide and dexamethasone as induction pre-transplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120:1589-1596.
- 5. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Final analysis of the IFM95-02 randomized trial. Blood. 2002;99:731-735.
- 6. Barlogie B, Jagannath S, Vesole D, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789-793.
- 7. Harousseau J. High-dose therapy in multiple myeloma. Annals of Oncology. 2002;13:49-54.
- 8. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
- 9. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28:2077-2084.
- 10. Greipp P, Miguel J, Dune B, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.
- 11. Kyle R, Rajkumar S. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3-9.
- 12. Dispenzieri A, Rajkumar S, Gertz M, et al. Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and riskadapted therapy (mSMART): consensus statement. Mayo Clin Proc. 2007;82:323-341.
- 13. Lee H, Min CK. Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice. Korean J Intern Med. 2016;31:809-819.
- 14. Kyle R, Rajkumar S. Treatment of Multiple Myeloma: A Comprehensive Review. Clin Lymphoma Myeloma. 2009;9:278-288.
- 15. Uy G, Rettig M, Cashen A. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther. 2008;8:1797-1804.
- 16. Mehdizadeh M, Hajifathali A, Tabarraee M, et al. Plerixafor in the Treatment of Stem Cell Mobilization Failure; First Experience in Iran. Iran J Pharm Res. 2013;12:189-191.
- 17. Kouroukis C, Varela N, Bredeson C, et al. Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario. Curr Oncol. 2016;23:409-430.
- 18. Lázár E, Köpeczi J, Kakucs E, et al. Difficulties of Mobilization and Harvesting of Hematopoietic Stem Cells in Heavily Pre-Treated Patients. Journal of Interdisciplinary Medicine. 2017;2:41-44.
- 19. Lázár E, Găzdac M, Jakab S, et al. Double Autologous Stem Cell Transplantation in a Case of nonsecretory Multiple Myeloma. Journal of Interdisciplinary Medicine. 2016;1:297-299.
- 20. Stewart A, Bergsagel P, Greipp P, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007;21:529-534.
- 21. McCarthy P, Owzar K, Hofmeister C, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770-1781.
- 22. Attal M, Harousseau J, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108:3289-3294.
- 23. Palumbo A, Bringhen S, Liberati A, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008;112:3107-3114.
- 24. Sonneveld P, Schmidt-Wolf I, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012;30:2946-2955.
- 25. Myeloma Trialists’ Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol. 2001;113:1020-1034.
- 26. Barlogie B, Kyle R, Anderson K, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24:929-936.
- 27. Jagannath S, Durie B, Wolf J Jr, et al. Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma. Blood. 2006;108:238a-239a.
- 28. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-1030.
- 29. Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008;112:3115-121.
- 30. San Miguel J, Schlag R, Khuageva N, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906-917.
- 31. Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol. 2014;32: 2712-2717.
- 32. Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15:333-342.
- 33. Benedek Lazar E, Benedek I, Benedek I Jr., et al. Double Hematological and Cardiologic Benefits of Autologous Stem Cell Transplantation in a Case of stage III B IgG Myeloma multiplex and Dilatative Cardiomyopathy – a Case Report. ARS Medica Tomitana. 2015;21:223-226.
- 34. Usmani S, Crowley J, Hoering A, et al. Improvement in long-term outcomes with successive total therapy trials for multiple myeloma: are patients now being cured? Leukemia. 2013;27:226-232.
- 35. Rizzo J, Somerfield M, Hagerty K, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008;26:132-149.
- 36. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28:2077-2084.
- 37. Chng W, Dispenzieri A, Chim C, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269-277.
- 38. Palumbo A, Rajkumar S, Dimopoulos M, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414-423.